Rheumatoid Arthritis News

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

Machine learning algorithms can be effective in predicting osteoporosis among patients with rheumatoid arthritis, as well as identifying new predictive factors, according to data published in Nature Scientific Reports.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

Patients with rheumatoid arthritis are increasingly receiving non-TNF inhibitors, which additionally demonstrate higher retention rates, compared with other biologics, according to data published in Nature Scientific Reports.

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.

Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.

In 2023, Healio had questions, the experts had answers.

In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.

SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.